Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
09:55am, Friday, 05'th Nov 2021
Bluebird (BLUE) delivered earnings and revenue surprises of -7.72% and -59.37%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
bluebird bio: Waiting For The Dust To Settle
03:43am, Wednesday, 03'rd Nov 2021
bluebird bio is preparing to spin off their cell therapy into a new publicly traded company, 2seventy bio. bluebird will focus on the company's gene therapy products. Although I am still fairly bullis
Bluebird Bio To Withdraw Marketing Of Skysona Gene Therapy In Europe
09:59am, Thursday, 21'st Oct 2021
Bluebird Bio Inc (NASDAQ: BLUE) will withdraw the regulatory marketing authorization for Skysona (elivaldogene autotemcel) in the European Union. The update comes as a part of the company's winding
Could This Beaten-Down Biotech Stock Be the Next Buyout Target?
06:25am, Wednesday, 20'th Oct 2021
This gene-therapy specialist may need some help turning things around.
bluebird (BLUE) Gives Details on Oncology Business Spinoff
10:58am, Tuesday, 12'th Oct 2021
bluebird (BLUE) provides information on stock distribution ratio and cash allocation for the planned spin-off of the oncology business.
Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?
10:00am, Monday, 11'th Oct 2021
These once-promising biotech stocks are trading at a fraction of their all-time highs right now.
bluebird bio Provides Update on Upcoming Planned Business Separation
04:54pm, Friday, 08'th Oct 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced the filing by 2seventy bio of an updated Form 10 Registration Statement with the U.S. Securities and Exchange Commi
bluebird (BLUE) Submits BLA for Gene-Therapy to Treat Thalassemia
01:49pm, Wednesday, 22'nd Sep 2021
bluebird (BLUE) files BLA with the FDA for its gene therapy, betibeglogene autotemcel (beti-cel), in patients with transfusion-dependent ??-thalassemia.
Bluebird Bio Files US Application For β-thalassemia Gene Therapy
07:03am, Wednesday, 22'nd Sep 2021
Bluebird Bio Inc (NASDAQ: BLUE) completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel) gene therapy. The application cover
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and D
7 Gene Editing Stocks Promising to Change our DNA
12:45pm, Wednesday, 15'th Sep 2021
Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared
Why Is Bluebird (BLUE) Down 13.3% Since Last Earnings Report?
01:16pm, Wednesday, 08'th Sep 2021
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?
7 Busted Biotech Stocks Due for a Rebound
12:25pm, Wednesday, 08'th Sep 2021
Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on
bluebird bio Secures $75 Million in Private Placement Equity Financing
07:30am, Wednesday, 08'th Sep 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivale
3 Beaten-Down Biotech Stocks to Buy Right Now
06:15am, Wednesday, 18'th Aug 2021
These biotech stocks might be down, but they're not out.
